ClinicalTrials.gg

Program

GLM101

A development code. Also written as “GLM101 (Part A, Double-blind)”.

Its studies are mostly in Ataxia, led by Glycomine.

Furthest: phase 3, since Feb 6, 20253 company-led studies, 2 open or runningNext primary completion: Sep 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Glycomine32 open or runningphase 3since Feb 6, 2025Aug 24, 2022Sep 2029phase 2 · NCT06657859

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 24, 2022First study: phase 2 study in Congenital disorder of glycosylation type 1AFirst studyNCT05549219 · 27 enrolled · United States, Spain, United Kingdom
  2. Oct 22, 2024Phase 2 study in Congenital disorder of glycosylation type 1ANCT06657859 · 90 planned · United States, Czechia, France and more
  3. Feb 6, 2025Phase 3 study in Congenital disorder of glycosylation type 1ANCT06892288 · 50 enrolled · United States, Belgium, Czechia and more

Ahead

  1. Sep 2029Primary completion: phase 2 study in Congenital disorder of glycosylation type 1ANCT06657859

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06892288Congenital disorder of glycosylation type 1A · United States, Belgium, Czechia and more3Active, not recruitingAug 5, 202650
NCT06657859Congenital disorder of glycosylation type 1A · United States, Czechia, France and more2By invitationSep 202990
NCT05549219Congenital disorder of glycosylation type 1A · United States, Spain, United Kingdom2CompletedNov 4, 202527

How it is read

Names in the registry

  • “GLM101”, 2 entries
  • “GLM101 (Part A, Double-blind)”, 1 entry

Codes read as this program: GLM101.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
GLM101 (Glycomine): development program | ClinicalTrials.gg